- Home
- BLFS
as 02-21-2025 4:00pm EST
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 1.2B | IPO Year: | 1989 |
| Target Price: | $29.43 | AVG Volume (30 days): | 240.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.50 - $29.55 | Next Earning Date: | 03-03-2025 |
| Revenue: | $146,957,000 | Revenue Growth: | 16.40% |
| Revenue Growth (this year): | -23.75% | Revenue Growth (next year): | -10.27% |
Stock Insider Trading Activity of BioLife Solutions Inc. (BLFS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Aebersold Sarah | BLFS | Chief Human Resources Officer | Feb 12 '25 | Sell | $26.54 | 53 | $1,406.62 | 60,191 | |
| Berard Todd | BLFS | Chief Marketing Officer | Feb 12 '25 | Sell | $26.54 | 102 | $2,707.08 | 106,962 | |
| Mathew Aby J. | BLFS | EVP & Chief Scientific Officer | Feb 12 '25 | Sell | $26.54 | 92 | $2,441.68 | 262,623 | |
| Wichterman Troy | BLFS | Chief Financial Officer | Feb 12 '25 | Sell | $26.54 | 159 | $4,219.86 | 121,620 | |
| Aebersold Sarah | BLFS | Chief Human Resources Officer | Jan 6 '25 | Sell | $27.02 | 240 | $6,484.80 | 60,191 | |
| Berard Todd | BLFS | Chief Marketing Officer | Jan 6 '25 | Sell | $27.02 | 343 | $9,267.86 | 106,962 | |
| Foster Karen A. | BLFS | Chief Quality and Operations | Jan 6 '25 | Sell | $27.02 | 328 | $8,862.56 | 156,645 | |
| Mathew Aby J. | BLFS | EVP & Chief Scientific Officer | Jan 6 '25 | Sell | $27.02 | 404 | $10,916.08 | 262,623 | |
| Wichterman Troy | BLFS | Chief Financial Officer | Jan 6 '25 | Sell | $27.02 | 987 | $26,668.74 | 121,620 | |
| Mathew Aby J. | BLFS | EVP & Chief Scientific Officer | Dec 16 '24 | Sell | $27.24 | 20,800 | $566,220.68 | 262,623 |
Latest BioLife Solutions Inc. News
BLFS Breaking Stock News: Dive into BLFS Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025
Argus Research
4 days ago
BLFS: Raising target price to $30.00
Simply Wall St.
5 days ago
Discover 3 US Stocks Estimated To Be Trading At Discounts Of Up To 41.5%
Argus Research
18 days ago
BLFS: Lowering target price to $28.00
Simply Wall St.
23 days ago
Breakeven On The Horizon For BioLife Solutions, Inc. (NASDAQ:BLFS)
Zacks
24 days ago
BioLife Solutions, Inc. (BLFS) Hit a 52 Week High, Can the Run Continue?
Argus Research
25 days ago
BLFS: Raising target price to $30.00
Zacks
a month ago
Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?
Compare BLFS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BLFS BioLife Solutions Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.